Увійти

Готові списки джерел за темами / Cystic fibrosis Gene therapy / Статті в журналах

Статті в журналах з теми "Cystic fibrosis Gene therapy"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Cystic fibrosis Gene therapy.

Автор: Grafiati

Опубліковано: 4 червня 2021

Оновлено: 11 лютого 2022

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Cystic fibrosis Gene therapy".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Griesenbach, Uta, Jane C. Davies, and Eric Alton. "Cystic fibrosis gene therapy." Current Opinion in Pulmonary Medicine 22, no. 6 (November 2016): 602–9. http://dx.doi.org/10.1097/mcp.0000000000000327.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Colledge, W. H., and M. J. Evans. "Cystic fibrosis gene therapy." British Medical Bulletin 51, no. 1 (January 1995): 82–90. http://dx.doi.org/10.1093/oxfordjournals.bmb.a072955.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Colledge, William H. "Cystic fibrosis gene therapy." Current Opinion in Genetics & Development 4, no. 3 (June 1994): 466–71. http://dx.doi.org/10.1016/0959-437x(94)90037-x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Prickett, Michelle, and Manu Jain. "Gene therapy in cystic fibrosis." Translational Research 161, no. 4 (April 2013): 255–64. http://dx.doi.org/10.1016/j.trsl.2012.12.001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Colledge, WH. "Gene therapy for cystic fibrosis." Lancet 349, no. 9060 (April 1997): 1249. http://dx.doi.org/10.1016/s0140-6736(97)26017-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Dodge, J. A. "Gene therapy for cystic fibrosis." Nature Medicine 1, no. 3 (March 1995): 182. http://dx.doi.org/10.1038/nm0395-182a.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Armstrong, D. K., S. Cunningham, J. C. Davies, and E. W. F. Alton. "Gene therapy in cystic fibrosis." Archives of Disease in Childhood 99, no. 5 (January 24, 2014): 465–68. http://dx.doi.org/10.1136/archdischild-2012-302158.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Wagner, MD, PhD, John A., and Phyllis Gardner, MD. "TOWARD CYSTIC FIBROSIS GENE THERAPY." Annual Review of Medicine 48, no. 1 (February 1997): 203–16. http://dx.doi.org/10.1146/annurev.med.48.1.203.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Flotte, Terence R., and Beth L. Laube. "Gene Therapy in Cystic Fibrosis." Chest 120, no. 3 (September 2001): 124S—131S. http://dx.doi.org/10.1378/chest.120.3_suppl.124s.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Alton, Eric, Stephen Smith, and Duncan Geddes. "Gene therapy for cystic fibrosis." Lancet 349, no. 9060 (April 1997): 1249–50. http://dx.doi.org/10.1016/s0140-6736(05)62441-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Janet E Larson, Y., Susan L. Morrow, and J. Craig Cohen. "Gene therapy for cystic fibrosis." Lancet 349, no. 9060 (April 1997): 1250. http://dx.doi.org/10.1016/s0140-6736(05)62442-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Turner, Gillian. "Gene therapy for cystic fibrosis." Lancet 349, no. 9060 (April 1997): 1250–51. http://dx.doi.org/10.1016/s0140-6736(05)62443-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Boyd, A. Christopher. "Gene therapy for cystic fibrosis." Expert Opinion on Therapeutic Patents 11, no. 1 (January 2001): 1–15. http://dx.doi.org/10.1517/13543776.11.1.1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Boyd, A. Christopher. "Gene therapy for cystic fibrosis." Expert Opinion on Therapeutic Patents 11, no. 2 (February 2001): 1–15. http://dx.doi.org/10.1517/13543776.11.2.1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Conese, Massimo, Sante Di Gioia, and Stefano Castellani. "Gene therapy for cystic fibrosis." Expert Opinion on Therapeutic Patents 18, no. 8 (August 2008): 929–43. http://dx.doi.org/10.1517/13543776.18.8.929.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Davies, Jane C., Duncan M. Geddes, and Eric W. F. W. Alton. "Gene therapy for cystic fibrosis." Journal of Gene Medicine 3, no. 5 (2001): 409–17. http://dx.doi.org/10.1002/jgm.200.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Bellon, G. "Cystic fibrosis (CF) gene therapy." Pediatric Pulmonology 23, S16 (April 1997): 278–79. http://dx.doi.org/10.1002/ppul.19502308144.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Johnson, Larry G. "Gene Therapy for Cystic Fibrosis." Chest 107, no. 2 (February 1995): 77S—83S. http://dx.doi.org/10.1378/chest.107.2_supplement.77s.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Rosenfeld, Melissa A., and Francis S. Collins. "Gene Therapy for Cystic Fibrosis." Chest 109, no. 1 (January 1996): 241–52. http://dx.doi.org/10.1378/chest.109.1.241.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Coutelle, C., N. Caplen, S. Hart, C. Huxley, and R. Williamson. "Gene therapy for cystic fibrosis." Archives of Disease in Childhood 68, no. 4 (April 1, 1993): 437–40. http://dx.doi.org/10.1136/adc.68.4.437.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Kitson, Chris, and Eric Alton. "Gene therapy for cystic fibrosis." Expert Opinion on Investigational Drugs 9, no. 7 (July 2000): 1523–35. http://dx.doi.org/10.1517/13543784.9.7.1523.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Davies, J. C., and E. W. F. W. Alton. "Gene Therapy for Cystic Fibrosis." Proceedings of the American Thoracic Society 7, no. 6 (October 28, 2010): 408–14. http://dx.doi.org/10.1513/pats.201004-029aw.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Luder, Elisabeth. "Gene Therapy for Cystic Fibrosis." Topics in Clinical Nutrition 14, no. 4 (September 1999): 22–30. http://dx.doi.org/10.1097/00008486-199909000-00004.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Mueller, Christian, and Terence R. Flotte. "Gene Therapy for Cystic Fibrosis." Clinical Reviews in Allergy & Immunology 35, no. 3 (July 4, 2008): 164–78. http://dx.doi.org/10.1007/s12016-008-8080-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Alton, E. W. F. W. "Gene therapy for cystic fibrosis." Journal of Inherited Metabolic Disease 18, no. 4 (1995): 501–7. http://dx.doi.org/10.1007/bf00710061.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Geddes, D. "Gene therapy for cystic fibrosis." Netherlands Journal of Medicine 46, no. 6 (June 1995): 306–12. http://dx.doi.org/10.1016/0300-2977(95)00024-h.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Coutelle, Charles. "Gene therapy approaches for cystic fibrosis." Biologicals 23, no. 1 (March 1995): 21–25. http://dx.doi.org/10.1016/1045-1056(95)90006-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Brown, Matt. "Gene therapy trials for cystic fibrosis." Drug Discovery Today 7, no. 15 (August 2002): 788–89. http://dx.doi.org/10.1016/s1359-6446(02)02393-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Higgins, Christopher F., Stephen C. Hyde, and Deborah R. Gill. "Towards Gene Therapy for Cystic Fibrosis." Biochemical Society Transactions 27, no. 5 (October 1, 1999): A137. http://dx.doi.org/10.1042/bst027a137a.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

ALTON, E. W. F. W. "Towards Gene Therapy For Cystic Fibrosis*." Journal of Pharmacy and Pharmacology 47, no. 5 (May 1995): 351–54. http://dx.doi.org/10.1111/j.2042-7158.1995.tb05809.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Ezzell, C. "Gene Therapy for Cystic Fibrosis Patients." Science News 142, no. 24 (December 12, 1992): 405. http://dx.doi.org/10.2307/4017870.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

O'Neal, WK, and AL Beaudet. "Somatic gene therapy for cystic fibrosis." Human Molecular Genetics 3, suppl_1 (September 1, 1994): 1497–502. http://dx.doi.org/10.1093/hmg/3.suppl_1.1497.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Griesenbach, Uta, Duncan M. Geddes, and Eric W. F. W. Alton. "Advances in cystic fibrosis gene therapy." Current Opinion in Pulmonary Medicine 10, no. 6 (November 2004): 542–46. http://dx.doi.org/10.1097/01.mcp.0000142102.91202.04.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Griesenbach, U., and E. W. F. W. Alton. "Moving forward: cystic fibrosis gene therapy." Human Molecular Genetics 22, R1 (August 4, 2013): R52—R58. http://dx.doi.org/10.1093/hmg/ddt372.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Parsons, DW. "Airway gene therapy and cystic fibrosis." Journal of Paediatrics and Child Health 41, no. 3 (March 2005): 94–96. http://dx.doi.org/10.1111/j.1440-1754.2005.00556.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Wilson, James. "Cystic Fibrosis: Strategies for Gene Therapy." Seminars in Respiratory and Critical Care Medicine 15, no. 05 (September 1994): 439–45. http://dx.doi.org/10.1055/s-2007-1006389.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Drittanti, L., MV Masciovecchio, J. Gabbarini, and M. Vega. "Cystic fibrosis: gene therapy or preventive gene transfer?" Gene Therapy 4, no. 10 (October 1997): 1001–3. http://dx.doi.org/10.1038/sj.gt.3300526.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Kutsev, S. I., V. L. Izhevskaya, and E. I. Kondratyeva. "Targeted therapy for cystic fibrosis." PULMONOLOGIYA 31, no. 2 (April 11, 2021): 226–36. http://dx.doi.org/10.18093/0869-0189-2021-31-2-226-236.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The basic therapy of cystic fibrosis is currently aimed at slowing down the pathological processes associated with a decrease in the CFTR protein activity (cystic fibrosis transmembrane conductance regulator) in the gastrointestinal tract and the respiratory system. The pancreatic insufficiency is well compensated by replacement therapy with microsphere enzyme preparations and a high-calorie diet rich in proteins and fat. Chronic treatment of cystic fibrosis-related lung disease aims to improve the clearance of the bronchial tree, suppressing chronic bacterial infection and local chronic inflammation. However, no therapy was available to correct the defect in the gene or its product until 2012.The aim was to analyze literature on CFTR modulators, including their efficacy and safety, and assess the potential for developing new modulators to treat cystic fibrosis.Materials. The review included literature data (45 publications) on the use of CFTR modulators and international websites’ data.Results. Since the discovery of the CFTR gene in 1989, more than 2000 mutations or variants of the CFTR gene (hereinafter referred to as genetic variants) have been described. They interfere with the synthesis of the CFTR protein, its transport to the apical membrane of the cell, or disrupt its function as a channel for chloride anions. Although it is currently not possible to completely replace the mutant gene with a normal copy, small molecules have been identified that can modify the mutant CFTR protein and amend its function. The potential therapeutic measures are determined by class of the mutation. In clinical practice, pharmacological modeling of ion transport is currently possible only with the use of CFTR modulators: correctors and potentiators. The review defines these groups of drugs and describes 4 licensed CFTR modulators, including molecules of ivacaftor, lumacaftor, tezacaftor, elexacaftor. The data on the promising emerging next generation modulators and the prospects for the personalized selection of drugs using the assays on intestinal organoids are presented.

39

LEE, Tim W. R., David A. MATTHEWS, and G. Eric BLAIR. "Novel molecular approaches to cystic fibrosis gene therapy." Biochemical Journal 387, no. 1 (March 22, 2005): 1–15. http://dx.doi.org/10.1042/bj20041923.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Gene therapy holds promise for the treatment of a range of inherited diseases, such as cystic fibrosis. However, efficient delivery and expression of the therapeutic transgene at levels sufficient to result in phenotypic correction of cystic fibrosis pulmonary disease has proved elusive. There are many reasons for this lack of progress, both macroscopically in terms of airway defence mechanisms and at the molecular level with regard to effective cDNA delivery. This review of approaches to cystic fibrosis gene therapy covers these areas in detail and highlights recent progress in the field. For gene therapy to be effective in patients with cystic fibrosis, the cDNA encoding the cystic fibrosis transmembrane conductance regulator protein must be delivered effectively to the nucleus of the epithelial cells lining the bronchial tree within the lungs. Expression of the transgene must be maintained at adequate levels for the lifetime of the patient, either by repeat dosage of the vector or by targeting airway stem cells. Clinical trials of gene therapy for cystic fibrosis have demonstrated proof of principle, but gene expression has been limited to 30 days at best. Results suggest that viral vectors such as adenovirus and adeno-associated virus are unsuited to repeat dosing, as the immune response reduces the effectiveness of each subsequent dose. Nonviral approaches, such as cationic liposomes, appear more suited to repeat dosing, but have been less effective. Current work regarding non-viral gene delivery is now focused on understanding the mechanisms involved in cell entry, endosomal escape and nuclear import of the transgene. There is now increasing evidence to suggest that additional ligands that facilitate endosomal escape or contain a nuclear localization signal may enhance liposome-mediated gene delivery. Much progress in this area has been informed by advances in our understanding of the mechanisms by which viruses deliver their genomes to the nuclei of host cells.

40

Castellani, Stefano, and Massimo Conese. "Lentiviral Vectors and Cystic Fibrosis Gene Therapy." Viruses 2, no. 2 (January 29, 2010): 395–412. http://dx.doi.org/10.3390/v2020395.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

&NA;. "Is gene therapy for cystic fibrosis realistic?" Inpharma Weekly &NA;, no. 1137 (May 1998): 6. http://dx.doi.org/10.2165/00128413-199811370-00008.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

DAGANI, RON. "Big step toward cystic fibrosis gene therapy." Chemical & Engineering News 70, no. 3 (January 20, 1992): 6. http://dx.doi.org/10.1021/cen-v070n003.p006.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Davies, Jane C. "Gene and cell therapy for cystic fibrosis." Paediatric Respiratory Reviews 7 (January 2006): S163—S165. http://dx.doi.org/10.1016/j.prrv.2006.04.214.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Tizzano, Eduardo F., and Manuel Buchwald. "Cystic fibrosis: Beyond the gene to therapy." Journal of Pediatrics 120, no. 3 (March 1992): 337–49. http://dx.doi.org/10.1016/s0022-3476(05)80895-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Jaffe, A., A. Bush, D. M. Geddes, and E. W. F. W. Alton. "Prospects for gene therapy in cystic fibrosis." Archives of Disease in Childhood 80, no. 3 (March 1, 1999): 286–89. http://dx.doi.org/10.1136/adc.80.3.286.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Alton, Eric WFW, and Duncan Geddes. "Gene Therapy: The Case for Cystic Fibrosis." Journal of the Royal Society of Medicine 90, no. 31_suppl (December 1997): 43–46. http://dx.doi.org/10.1177/014107689709031s09.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Caplen, Natasha J. "Cystic fibrosis gene therapy trials and tribulations." Trends in Molecular Medicine 7, no. 11 (November 2001): 488. http://dx.doi.org/10.1016/s1471-4914(01)02168-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Davies, Jane C., Duncan M. Geddes, and Eric W. F. W. Alton. "Prospects for gene therapy for cystic fibrosis." Molecular Medicine Today 4, no. 7 (July 1998): 292–99. http://dx.doi.org/10.1016/s1357-4310(98)01265-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Fox, Jeffrey L. "NIHRAC okays gene therapy for cystic fibrosis." Nature Biotechnology 11, no. 1 (January 1993): 29. http://dx.doi.org/10.1038/nbt0193-28b.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Griesenbach, U., S. Ferrari, D. M. Geddes, and E. W. F. W. Alton. "Gene Therapy Progress and Prospects: Cystic fibrosis." Gene Therapy 9, no. 20 (October 2002): 1344–50. http://dx.doi.org/10.1038/sj.gt.3301791.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.